Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2021

View Archived Issues

Dosing begins in phase II trial of CGB-400 for rosacea

Dr. Reddy's licenses anti-BCMA CAR T PRG-1801 for India

Sumitomo Dainippon Pharma to study DSP-0038 in phase I for Alzheimer's disease psychosis

New METTL3 inhibitors identified at Accent Therapeutics

Merck & Co. divulges new LRRK2 inhibitors

New hepatitis C virus NS5A protein inhibitors discovered at Alla Chem

Alphala patents anticancer compounds

Sunshine Lake Pharma describes new mineralocorticoid receptor antagonists

Lentiviral gene transfer used to develop model of TGF-beta-2-induced ocular hypertension

Protein kinase analysis identifies potential therapeutic targets for Friedreich's ataxia

H. pylori oncoprotein-induced genome instability may underlie gastric cancer

Dosing initiates in phase I study of GFB-024 in severe insulin-resistant diabetic nephropathy

ReGenTree reports further phase III data on RGN-259 for dry eye syndrome

FDA approves Zynrelef for postsurgical analgesia

Stem cell lentiviral therapy restores neuromuscular symptoms in models of Pompe disease

Enrollment opens in phase I/II study of BLU-945 in patients with EGFR mutant NSCLC

TG Therapeutics initiates phase Ib study of TG-1801 in B-cell lymphoma or CLL

Preliminary clinical data of highly purified chimeric antigen receptor T-cell therapy targeting CD19

Astellas studies ASP-0367 in phase II/III for primary mitochondrial myopathy

R0.6C vaccine candidate for malaria enters first-in-human study

Phase Ib/IIa trial evaluates tigilanol tiglate with pembrolizumab in advanced melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...